04.06.26 -- Advancing Next-Generation Biologics: From Cell Line Innovation To Complex Modalities

By combining improved productivity with speed and reliability, S-CHOice® 2G helps biopharmaceutical companies optimize their manufacturing strategies, reduce overall costs, and respond more effectively to market demands.

Bispecific antibodies (bsAbs) enable enhanced therapeutic efficacy through dual-targeting, but their complex structure poses significant manufacturing and purification challenges that require innovative solutions to ensure product purity and clinical viability.

Accelerate your cancer therapy development with patient-derived organoids — high-fidelity models that enhance translational confidence, streamline discovery, and bring promising treatments to the clinic faster.